ID   PO4F1_MOUSE             Reviewed;         421 AA.
AC   P17208; E9QPT6;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   27-JUL-2011, sequence version 3.
DT   07-APR-2021, entry version 173.
DE   RecName: Full=POU domain, class 4, transcription factor 1;
DE   AltName: Full=Brain-specific homeobox/POU domain protein 3A;
DE            Short=Brain-3A;
DE            Short=Brn-3A;
DE   AltName: Full=Brn-3.0;
GN   Name=Pou4f1; Synonyms=Brn-3, Brn3, Brn3a;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND TISSUE SPECIFICITY.
RX   PubMed=8162704; DOI=10.1159/000133709;
RA   Theil T., Zechner U., Klett C., Adolph S., Moeroey T.;
RT   "Chromosomal localization and sequences of the murine Brn-3 family of
RT   developmental control genes.";
RL   Cytogenet. Cell Genet. 66:267-271(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S., She X.,
RA   Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W., Kapustin Y.,
RA   Meric P., Maglott D., Birtle Z., Marques A.C., Graves T., Zhou S.,
RA   Teague B., Potamousis K., Churas C., Place M., Herschleb J., Runnheim R.,
RA   Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z., Lindblad-Toh K.,
RA   Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of the
RT   mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 286-401.
RC   STRAIN=T6 / TW1; TISSUE=Testis;
RX   PubMed=1970171; DOI=10.1093/nar/18.6.1634;
RA   Goldsborough A., Ashworth A., Willison K.R.;
RT   "Cloning and sequencing of POU-boxes expressed in mouse testis.";
RL   Nucleic Acids Res. 18:1634-1634(1990).
RN   [4]
RP   ALTERNATIVE SPLICING, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=8290353; DOI=10.1093/nar/21.25.5921;
RA   Theil T., McLean-Hunter S., Zoernig M., Moeroey T.;
RT   "Mouse Brn-3 family of POU transcription factors: a new aminoterminal
RT   domain is crucial for the oncogenic activity of Brn-3a.";
RL   Nucleic Acids Res. 21:5921-5929(1993).
RN   [5]
RP   INTERACTION WITH POU4F2 (ISOFORM 1).
RX   PubMed=8537352; DOI=10.1074/jbc.270.52.30958;
RA   Theil T., Roedel B., Spiegelhalter F., Moeroey T.;
RT   "Short isoform of POU factor Brn-3b can form a heterodimer with Brn-3a that
RT   is inactive for octamer motif binding.";
RL   J. Biol. Chem. 270:30958-30964(1995).
RN   [6]
RP   FUNCTION, DOMAIN, AND DNA-BINDING.
RX   PubMed=8621561; DOI=10.1074/jbc.271.15.9108;
RA   Budhram-Mahadeo V., Morris P.J., Lakin N.D., Dawson S.J., Latchman D.S.;
RT   "The different activities of the two activation domains of the Brn-3a
RT   transcription factor are dependent on the context of the binding site.";
RL   J. Biol. Chem. 271:9108-9113(1996).
RN   [7]
RP   DEVELOPMENTAL STAGE.
RX   PubMed=8637595; DOI=10.1038/381603a0;
RA   Erkman L., McEvilly R.J., Luo L., Ryan A.K., Hooshmand F., O'Connell S.M.,
RA   Keithley E.M., Rapaport D.H., Ryan A.F., Rosenfeld M.G.;
RT   "Role of transcription factors Brn-3.1 and Brn-3.2 in auditory and visual
RT   system development.";
RL   Nature 381:603-606(1996).
RN   [8]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=8876243; DOI=10.1073/pnas.93.21.11950;
RA   Xiang M., Gan L., Zhou L., Klein W.H., Nathans J.;
RT   "Targeted deletion of the mouse POU domain gene Brn-3a causes selective
RT   loss of neurons in the brainstem and trigeminal ganglion, uncoordinated
RT   limb movement, and impaired suckling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:11950-11955(1996).
RN   [9]
RP   FUNCTION, DOMAIN, AND MUTAGENESIS OF VAL-378.
RX   PubMed=8972215; DOI=10.1128/mcb.17.1.345;
RA   Smith M.D., Dawson S.J., Latchman D.S.;
RT   "The Brn-3a transcription factor induces neuronal process outgrowth and the
RT   coordinate expression of genes encoding synaptic proteins.";
RL   Mol. Cell. Biol. 17:345-354(1997).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH ESR1 (ISOFORM 1).
RX   PubMed=9448000; DOI=10.1128/mcb.18.2.1029;
RA   Budhram-Mahadeo V., Parker M., Latchman D.S.;
RT   "POU transcription factors Brn-3a and Brn-3b interact with the estrogen
RT   receptor and differentially regulate transcriptional activity via an
RT   estrogen response element.";
RL   Mol. Cell. Biol. 18:1029-1041(1998).
RN   [11]
RP   FUNCTION, AND MUTAGENESIS OF VAL-378.
RX   PubMed=9694219; DOI=10.1097/00001756-199807130-00029;
RA   Dawson S.J., Palmer R.D., Morris P.J., Latchman D.S.;
RT   "Functional role of position 22 in the homeodomain of Brn-3 transcription
RT   factors.";
RL   NeuroReport 9:2305-2309(1998).
RN   [12]
RP   FUNCTION, FUNCTION (ISOFORM 2), DOMAIN, AND MUTAGENESIS OF VAL-378.
RX   PubMed=9722627; DOI=10.1093/nar/26.18.4100;
RA   Smith M.D., Dawson S.J., Boxer L.M., Latchman D.S.;
RT   "The N-terminal domain unique to the long form of the Brn-3a transcription
RT   factor is essential to protect neuronal cells from apoptosis and for the
RT   activation of Bbcl-2 gene expression.";
RL   Nucleic Acids Res. 26:4100-4107(1998).
RN   [13]
RP   FUNCTION.
RX   PubMed=10640682; DOI=10.1016/s0169-328x(99)00271-5;
RA   Smith M.D., Ensor E.A., Stohl L., Wagner J.A., Latchman D.S.;
RT   "Regulation of NGFI-A (Egr-1) gene expression by the POU domain
RT   transcription factor Brn-3a.";
RL   Brain Res. Mol. Brain Res. 74:117-125(1999).
RN   [14]
RP   FUNCTION.
RX   PubMed=12441296; DOI=10.1242/dev.00194;
RA   Trieu M., Ma A., Eng S.R., Fedtsova N., Turner E.E.;
RT   "Direct autoregulation and gene dosage compensation by POU-domain
RT   transcription factor Brn3a.";
RL   Development 130:111-121(2003).
RN   [15]
RP   FUNCTION, FUNCTION (ISOFORM 2), AND INTERACTION WITH RIT2.
RX   PubMed=12934100; DOI=10.1038/sj.onc.1206635;
RA   Calissano M., Latchman D.S.;
RT   "Functional interaction between the small GTP-binding protein Rin and the
RT   N-terminal of Brn-3a transcription factor.";
RL   Oncogene 22:5408-5414(2003).
RN   [16]
RP   FUNCTION, DNA-BINDING, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND
RP   INDUCTION.
RX   PubMed=17668438; DOI=10.1002/jcb.21257;
RA   Schulze-Spaete U., Battaglino R., Fu J., Sharma A., Vokes M., Stashenko P.;
RT   "Brn3 transcription factors control terminal osteoclastogenesis.";
RL   J. Cell. Biochem. 102:1-12(2007).
RN   [17]
RP   FUNCTION, DISRUPTION PHENOTYPE, AND DEVELOPMENTAL STAGE.
RX   PubMed=22326227; DOI=10.1016/j.ydbio.2012.01.021;
RA   Zou M., Li S., Klein W.H., Xiang M.;
RT   "Brn3a/Pou4f1 regulates dorsal root ganglion sensory neuron specification
RT   and axonal projection into the spinal cord.";
RL   Dev. Biol. 364:114-127(2012).
CC   -!- FUNCTION: Multifunctional transcription factor with different regions
CC       mediating its different effects (PubMed:10640682, PubMed:8621561,
CC       PubMed:9694219, PubMed:9722627). Acts by binding (via its C-terminal
CC       domain) to sequences related to the consensus octamer motif 5'-
CC       ATGCAAAT-3' in the regulatory regions of its target genes
CC       (PubMed:8621561, PubMed:17668438). Regulates the expression of specific
CC       genes involved in differentiation and survival within a subset of
CC       neuronal lineages. It has been shown that activation of some of these
CC       genes requires its N-terminal domain, maybe through a neuronal-specific
CC       cofactor (PubMed:12934100). Ativates BCL2 expression and protects
CC       neuronal cells from apoptosis (via the N-terminal domain)
CC       (PubMed:9722627). Induces neuronal process outgrowth and the coordinate
CC       expression of genes encoding synaptic proteins (PubMed:8972215). Exerts
CC       its major developmental effects in somatosensory neurons and in
CC       brainstem nuclei involved in motor control. Stimulates the binding
CC       affinity of the nuclear estrogene receptor ESR1 to DNA estrogen
CC       response element (ERE), and hence modulates ESR1-induced
CC       transcriptional activity (PubMed:9448000). May positively regulate
CC       POU4F2 and POU4F3 (PubMed:8876243). Regulates dorsal root ganglion
CC       sensory neuron specification and axonal projection into the spinal cord
CC       (PubMed:22326227). Plays a role in TNFSF11-mediated terminal osteoclast
CC       differentiation (PubMed:17668438). Negatively regulates its own
CC       expression interacting directly with a highly conserved autoregulatory
CC       domain surrounding the transcription initiation site (PubMed:12441296).
CC       {ECO:0000269|PubMed:10640682, ECO:0000269|PubMed:12441296,
CC       ECO:0000269|PubMed:12934100, ECO:0000269|PubMed:17668438,
CC       ECO:0000269|PubMed:22326227, ECO:0000269|PubMed:8621561,
CC       ECO:0000269|PubMed:8876243, ECO:0000269|PubMed:8972215,
CC       ECO:0000269|PubMed:9448000, ECO:0000269|PubMed:9694219,
CC       ECO:0000269|PubMed:9722627}.
CC   -!- FUNCTION: [Isoform 2]: Able to act as transcription factor, cannot
CC       regulate the expression of the same subset of genes than isoform 1
CC       (PubMed:12934100). Does not have antiapoptotic effect on neuronal cells
CC       (PubMed:9722627). {ECO:0000269|PubMed:12934100,
CC       ECO:0000269|PubMed:9722627}.
CC   -!- SUBUNIT: Interacts (via N-terminus) with RIT2; the interaction controls
CC       POU4F1 transactivation activity on some neuronal target genes
CC       (PubMed:12934100). Isoform 1 interacts with POU4F2 isoform 2; this
CC       interaction inhibits both POU4F1 DNA-binding and transcriptional
CC       activities (PubMed:8537352). Isoform 1 interacts (C-terminus) with ESR1
CC       (via DNA-binding domain); this interaction decreases the estrogen
CC       receptor ESR1 transcriptional activity in a DNA- and ligand 17-beta-
CC       estradiol-independent manner (PubMed:9448000).
CC       {ECO:0000269|PubMed:12934100, ECO:0000269|PubMed:8537352,
CC       ECO:0000269|PubMed:9448000}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:17668438}. Cytoplasm
CC       {ECO:0000269|PubMed:17668438}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Brn-3A-Long {ECO:0000303|PubMed:8290353};
CC         IsoId=P17208-1; Sequence=Displayed;
CC       Name=2 {ECO:0000303|PubMed:8290353}; Synonyms=Brn-3A-Short
CC       {ECO:0000303|PubMed:8290353};
CC         IsoId=P17208-2; Sequence=VSP_058637;
CC   -!- TISSUE SPECIFICITY: Expressed in mature osteoclasts (at protein level)
CC       (PubMed:17668438). Brain, peripheral sensory nervous system and retina
CC       (PubMed:8162704). In the adult nervous system, predominates in the
CC       medial habenula, superficial gray of the superior colliculus, red
CC       nucleus, mesencephalic nucleus of the trigeminal ganglion, nucleus
CC       ambiguus, inferior olivary nucleus, and peripheral sensory ganglia
CC       (PubMed:8290353). {ECO:0000269|PubMed:17668438,
CC       ECO:0000269|PubMed:8162704, ECO:0000269|PubMed:8290353}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in the spinal cord from 11 dpc to the
CC       adult stage (PubMed:8290353). As early as 10.5 dpc to 15.5 dpc,
CC       strongly expressed in all dorsal root ganglion neurons
CC       (PubMed:22326227). In retinal ganglion cells, expression starts at 15.5
CC       dpc and exhibits a slow decrease with moderate levels detectable at P8
CC       (PubMed:8637595). {ECO:0000269|PubMed:22326227,
CC       ECO:0000269|PubMed:8290353, ECO:0000269|PubMed:8637595}.
CC   -!- INDUCTION: Up-regulated by the osteoclast differentiation factor
CC       TNFSF11 (PubMed:17668438). {ECO:0000269|PubMed:17668438}.
CC   -!- DOMAIN: The C-terminal domain is able to act as both DNA-binding domain
CC       and a transcriptional activator. The N-terminal domain is also required
CC       for transactivation activity on some target genes acting as a discrete
CC       activation domain (PubMed:8621561, PubMed:9722627). Neurite outgrowth
CC       and expression of genes required for synapse formation are primarily
CC       dependent on the C-terminal domain, however the N-terminal domain is
CC       required for maximal induction (PubMed:8972215).
CC       {ECO:0000269|PubMed:8621561, ECO:0000269|PubMed:8972215,
CC       ECO:0000269|PubMed:9722627}.
CC   -!- DISRUPTION PHENOTYPE: Mutants have defective suckling and uncoordinated
CC       limb and trunk movements, leading to early postnatal death. They show a
CC       loss of neurons in the trigerminal ganglia, the medial habenula, the
CC       red nucleus and the caudal region of the inferior olivary nucleus
CC       (PubMed:8876243). Mutant dorsal root ganglions are defective in sensory
CC       neuron specification, and sensory afferent axons fail to form normal
CC       trajectories in the spinal cord (PubMed:22326227).
CC       {ECO:0000269|PubMed:22326227, ECO:0000269|PubMed:8876243}.
CC   -!- SIMILARITY: Belongs to the POU transcription factor family. Class-4
CC       subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; S69350; AAB30577.2; -; Genomic_DNA.
DR   EMBL; AC121997; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; X51959; CAA36218.1; -; mRNA.
DR   CCDS; CCDS27319.1; -. [P17208-1]
DR   RefSeq; NP_035273.3; NM_011143.4. [P17208-1]
DR   RefSeq; XP_006518768.1; XM_006518705.3. [P17208-1]
DR   RefSeq; XP_006518769.1; XM_006518706.3. [P17208-1]
DR   SMR; P17208; -.
DR   BioGRID; 202310; 2.
DR   STRING; 10090.ENSMUSP00000060798; -.
DR   PhosphoSitePlus; P17208; -.
DR   PaxDb; P17208; -.
DR   PRIDE; P17208; -.
DR   ProteomicsDB; 289775; -. [P17208-1]
DR   ProteomicsDB; 289776; -. [P17208-2]
DR   Antibodypedia; 24689; 150 antibodies.
DR   Ensembl; ENSMUST00000053016; ENSMUSP00000060798; ENSMUSG00000048349. [P17208-1]
DR   GeneID; 18996; -.
DR   KEGG; mmu:18996; -.
DR   UCSC; uc007uxb.2; mouse. [P17208-1]
DR   CTD; 5457; -.
DR   MGI; MGI:102525; Pou4f1.
DR   eggNOG; KOG1168; Eukaryota.
DR   GeneTree; ENSGT00940000162154; -.
DR   HOGENOM; CLU_013065_0_0_1; -.
DR   InParanoid; P17208; -.
DR   OMA; DIMDHIG; -.
DR   OrthoDB; 929123at2759; -.
DR   TreeFam; TF316413; -.
DR   Reactome; R-MMU-6804759; Regulation of TP53 Activity through Association with Co-factors.
DR   BioGRID-ORCS; 18996; 0 hits in 52 CRISPR screens.
DR   ChiTaRS; Pou4f1; mouse.
DR   PRO; PR:P17208; -.
DR   Proteomes; UP000000589; Chromosome 14.
DR   RNAct; P17208; protein.
DR   Bgee; ENSMUSG00000048349; Expressed in trigeminal ganglion and 184 other tissues.
DR   Genevisible; P17208; MM.
DR   GO; GO:0000785; C:chromatin; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; IDA:MGI.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0090575; C:RNA polymerase II transcription regulator complex; IDA:ARUK-UCL.
DR   GO; GO:0003682; F:chromatin binding; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0003677; F:DNA binding; IDA:MGI.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:UniProtKB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IMP:MGI.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:BHF-UCL.
DR   GO; GO:0051020; F:GTPase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0001103; F:RNA polymerase II repressing transcription factor binding; ISO:MGI.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; ISO:MGI.
DR   GO; GO:0003697; F:single-stranded DNA binding; IDA:UniProtKB.
DR   GO; GO:0021535; P:cell migration in hindbrain; IMP:MGI.
DR   GO; GO:0071345; P:cellular response to cytokine stimulus; IDA:UniProtKB.
DR   GO; GO:0071392; P:cellular response to estradiol stimulus; IDA:UniProtKB.
DR   GO; GO:0021953; P:central nervous system neuron differentiation; IMP:MGI.
DR   GO; GO:0021986; P:habenula development; IMP:MGI.
DR   GO; GO:0007507; P:heart development; IGI:ARUK-UCL.
DR   GO; GO:0060384; P:innervation; IMP:MGI.
DR   GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IMP:UniProtKB.
DR   GO; GO:0007498; P:mesoderm development; IMP:MGI.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IGI:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:ARUK-UCL.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IMP:BHF-UCL.
DR   GO; GO:0043069; P:negative regulation of programmed cell death; IMP:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:2001208; P:negative regulation of transcription elongation by RNA polymerase I; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0007399; P:nervous system development; IDA:MGI.
DR   GO; GO:0030182; P:neuron differentiation; IMP:MGI.
DR   GO; GO:0048665; P:neuron fate specification; IMP:BHF-UCL.
DR   GO; GO:0031175; P:neuron projection development; IDA:UniProtKB.
DR   GO; GO:0048935; P:peripheral nervous system neuron development; IMP:BHF-UCL.
DR   GO; GO:0048934; P:peripheral nervous system neuron differentiation; IMP:MGI.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IGI:MGI.
DR   GO; GO:0071158; P:positive regulation of cell cycle arrest; IMP:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0045672; P:positive regulation of osteoclast differentiation; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:2000679; P:positive regulation of transcription regulatory region DNA binding; IDA:UniProtKB.
DR   GO; GO:0051355; P:proprioception involved in equilibrioception; IMP:MGI.
DR   GO; GO:0051090; P:regulation of DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0050767; P:regulation of neurogenesis; IMP:MGI.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IMP:MGI.
DR   GO; GO:0048880; P:sensory system development; IMP:BHF-UCL.
DR   GO; GO:0001967; P:suckling behavior; IMP:MGI.
DR   GO; GO:0021559; P:trigeminal nerve development; IMP:BHF-UCL.
DR   GO; GO:0003223; P:ventricular compact myocardium morphogenesis; IMP:UniProtKB.
DR   CDD; cd00086; homeodomain; 1.
DR   CDD; cd00093; HTH_XRE; 1.
DR   Gene3D; 1.10.260.40; -; 1.
DR   InterPro; IPR001387; Cro/C1-type_HTH.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR017970; Homeobox_CS.
DR   InterPro; IPR001356; Homeobox_dom.
DR   InterPro; IPR010982; Lambda_DNA-bd_dom_sf.
DR   InterPro; IPR013847; POU.
DR   InterPro; IPR015584; POU4-TF1.
DR   InterPro; IPR000327; POU_dom.
DR   PANTHER; PTHR11636:SF42; PTHR11636:SF42; 1.
DR   Pfam; PF00046; Homeodomain; 1.
DR   Pfam; PF00157; Pou; 1.
DR   PRINTS; PR00028; POUDOMAIN.
DR   SMART; SM00389; HOX; 1.
DR   SMART; SM00352; POU; 1.
DR   SUPFAM; SSF46689; SSF46689; 1.
DR   SUPFAM; SSF47413; SSF47413; 1.
DR   PROSITE; PS00027; HOMEOBOX_1; 1.
DR   PROSITE; PS50071; HOMEOBOX_2; 1.
DR   PROSITE; PS00035; POU_1; 1.
DR   PROSITE; PS00465; POU_2; 1.
DR   PROSITE; PS51179; POU_3; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cytoplasm; Developmental protein; DNA-binding;
KW   Homeobox; Nucleus; Reference proteome; Transcription;
KW   Transcription regulation.
FT   CHAIN           1..421
FT                   /note="POU domain, class 4, transcription factor 1"
FT                   /id="PRO_0000100737"
FT   DOMAIN          262..339
FT                   /note="POU-specific"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00530"
FT   DNA_BIND        357..416
FT                   /note="Homeobox"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00108"
FT   MOTIF           57..66
FT                   /note="POU-IV box"
FT   COMPBIAS        100..108
FT                   /note="Poly-His"
FT   COMPBIAS        130..187
FT                   /note="Gly-rich"
FT   COMPBIAS        205..258
FT                   /note="Ala-rich"
FT   VAR_SEQ         1..84
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_058637"
FT   MUTAGEN         378
FT                   /note="V->I: Abolishes transcriptional activity. Increases
FT                   transcriptional repression. Disrupts induction of neurite
FT                   outgrowth and expression of synaptic genes. No effect on
FT                   transactivation of BCL2 expression."
FT                   /evidence="ECO:0000269|PubMed:8972215,
FT                   ECO:0000269|PubMed:9694219, ECO:0000269|PubMed:9722627"
FT   CONFLICT        179
FT                   /note="G -> A (in Ref. 1; AAB30577)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   421 AA;  42767 MW;  64EC98E5C0CF79E2 CRC64;
     MMSMNSKQPH FAMHPTLPEH KYPSLHSSSE AIRRACLPTP PLQSNLFASL DETLLARAEA
     LAAVDIAVSQ GKSHPFKPDA TYHTMNSVPC TSTSTVPLAH HHHHHHHHQA LEPGDLLDHI
     SSPSLALMAG AGGAGAAGGG GGAHDGPGGG GGPGGGGGPG GGGPGGGGGG GGPGGGGGGP
     GGGLLGGSAH PHPHMHGLGH LSHPAAAAAM NMPSGLPHPG LVAAAAHHGA AAAAAAAAAG
     QVAAASAAAA VVGAAGLASI CDSDTDPREL EAFAERFKQR RIKLGVTQAD VGSALANLKI
     PGVGSLSQST ICRFESLTLS HNNMIALKPI LQAWLEEAEG AQREKMNKPE LFNGGEKKRK
     RTSIAAPEKR SLEAYFAVQP RPSSEKIAAI AEKLDLKKNV VRVWFCNQRQ KQKRMKFSAT
     Y
//
